PMID- 37383609
OWN - NLM
STAT- MEDLINE
DCOM- 20230703
LR  - 20230703
IS  - 2314-7156 (Electronic)
IS  - 2314-8861 (Print)
IS  - 2314-7156 (Linking)
VI  - 2023
DP  - 2023
TI  - Serum TGF-beta1 and CD14 Predicts Response to Anti-TNF-alpha Therapy in IBD.
PG  - 1535484
LID - 10.1155/2023/1535484 [doi]
LID - 1535484
AB  - BACKGROUND: Tumor necrosis factor-alpha (TNF-alpha) agonists revolutionized 
      therapeutic algorithms in inflammatory bowel disease (IBD) management. However, 
      approximately every third IBD patient does not respond to this therapy in the 
      long term, which delays efficient control of the intestinal inflammation. 
      METHODS: We analyzed the power of serum biomarkers to predict the failure of 
      anti-TNF-alpha. We collected serum of 38 IBD patients at therapy prescription and 38 
      weeks later and analyzed them with relation to therapy response (no-, partial-, 
      and full response). We used enzyme-linked immunosorbent assay to quantify 16 
      biomarkers related to gut barrier (intestinal fatty acid-binding protein, liver 
      fatty acid-binding protein, trefoil factor 3, and interleukin (IL)-33), microbial 
      translocation, immune system regulation (TNF-alpha, CD14, lipopolysaccharide-binding 
      protein, mannan-binding lectin, IL-18, transforming growth factor-beta1 (TGF-beta1), 
      osteoprotegerin (OPG), insulin-like growth factor 2 (IGF-2), 
      endocrine-gland-derived vascular endothelial growth factor), and matrix 
      metalloproteinase system (MMP-9, MMP-14, and tissue inhibitors of 
      metalloproteinase-1). RESULTS: We found that future full-responders have 
      different biomarker profiles than non-responders, while partial-responders cannot 
      be distinguished from either group. When future non-responders were compared to 
      responders, their baseline contained significantly more TGF-beta1, less CD14, and 
      increased level of MMP-9, and concentration of these factors could predict 
      non-responders with high accuracy (AUC = 0.938). Interestingly, during the 38 
      weeks, levels of MMP-9 decreased in all patients, irrespective of the outcome, 
      while OPG, IGF-2, and TGF-beta1 were higher in non-responders compared to 
      full-responders both at the beginning and the end of the treatment. CONCLUSIONS: 
      The TGF-beta1 and CD14 can distinguish non-responders from responders. The changes 
      in biomarker dynamics during the therapy suggest that growth factors (such as 
      OPG, IGF-2, and TGF-beta) are not markedly influenced by the treatment and that 
      anti-TNF-alpha therapy decreases MMP-9 without influencing the treatment outcome.
CI  - Copyright (c) 2023 Stepan Coufal et al.
FAU - Coufal, Stepan
AU  - Coufal S
AUID- ORCID: 0000-0001-6950-1813
AD  - Laboratory of Cellular and Molecular Immunology, Institute of Microbiology of the 
      Czech Academy of Sciences, Prague, Czech Republic.
FAU - Kverka, Miloslav
AU  - Kverka M
AD  - Laboratory of Cellular and Molecular Immunology, Institute of Microbiology of the 
      Czech Academy of Sciences, Prague, Czech Republic.
FAU - Kreisinger, Jakub
AU  - Kreisinger J
AD  - Laboratory of Animal Evolutionary Biology, Faculty of Science, Department of 
      Zoology, Charles University, Prague, Czech Republic.
FAU - Thon, Tomas
AU  - Thon T
AD  - Laboratory of Cellular and Molecular Immunology, Institute of Microbiology of the 
      Czech Academy of Sciences, Prague, Czech Republic.
FAU - Rob, Filip
AU  - Rob F
AD  - Second Faculty of Medicine, University Hospital Bulovka, Dermatovenerology 
      Department, Charles University, Prague, Czech Republic.
FAU - Kolar, Martin
AU  - Kolar M
AD  - ISCARE a.s., IBD Clinical and Research Centre, Prague, Czech Republic.
FAU - Reiss, Zuzana
AU  - Reiss Z
AD  - Laboratory of Cellular and Molecular Immunology, Institute of Microbiology of the 
      Czech Academy of Sciences, Prague, Czech Republic.
FAU - Schierova, Dagmar
AU  - Schierova D
AD  - Laboratory of Cellular and Molecular Immunology, Institute of Microbiology of the 
      Czech Academy of Sciences, Prague, Czech Republic.
FAU - Kostovcikova, Klara
AU  - Kostovcikova K
AD  - Laboratory of Cellular and Molecular Immunology, Institute of Microbiology of the 
      Czech Academy of Sciences, Prague, Czech Republic.
FAU - Roubalova, Radka
AU  - Roubalova R
AD  - Laboratory of Cellular and Molecular Immunology, Institute of Microbiology of the 
      Czech Academy of Sciences, Prague, Czech Republic.
FAU - Bajer, Lukas
AU  - Bajer L
AD  - Laboratory of Cellular and Molecular Immunology, Institute of Microbiology of the 
      Czech Academy of Sciences, Prague, Czech Republic.
AD  - Department of Gastroenterology and Hepatology, Institute for Clinical and 
      Experimental Medicine, Prague, Czech Republic.
FAU - Jackova, Zuzana
AU  - Jackova Z
AD  - Laboratory of Cellular and Molecular Immunology, Institute of Microbiology of the 
      Czech Academy of Sciences, Prague, Czech Republic.
FAU - Mihula, Martin
AU  - Mihula M
AD  - Laboratory of Cellular and Molecular Immunology, Institute of Microbiology of the 
      Czech Academy of Sciences, Prague, Czech Republic.
FAU - Drastich, Pavel
AU  - Drastich P
AD  - Department of Gastroenterology and Hepatology, Institute for Clinical and 
      Experimental Medicine, Prague, Czech Republic.
FAU - Tresnak Hercogova, Jana
AU  - Tresnak Hercogova J
AD  - Second Faculty of Medicine, University Hospital Bulovka, Dermatovenerology 
      Department, Charles University, Prague, Czech Republic.
AD  - Dermatology Prof. Hercogova, Center for Biological Therapy, Prague, Czech 
      Republic.
FAU - Novakova, Michaela
AU  - Novakova M
AD  - Second Faculty of Medicine, University Hospital Bulovka, Dermatovenerology 
      Department, Charles University, Prague, Czech Republic.
FAU - Vasatko, Martin
AU  - Vasatko M
AD  - ISCARE a.s., IBD Clinical and Research Centre, Prague, Czech Republic.
FAU - Lukas, Milan
AU  - Lukas M
AD  - ISCARE a.s., IBD Clinical and Research Centre, Prague, Czech Republic.
AD  - Institute of Medical Biochemistry and Laboratory Diagnostics, General University 
      Hospital and First Faculty of Medicine, Charles University, Prague, Czech 
      Republic.
FAU - Tlaskalova-Hogenova, Helena
AU  - Tlaskalova-Hogenova H
AD  - Laboratory of Cellular and Molecular Immunology, Institute of Microbiology of the 
      Czech Academy of Sciences, Prague, Czech Republic.
FAU - Jiraskova Zakostelska, Zuzana
AU  - Jiraskova Zakostelska Z
AUID- ORCID: 0000-0002-6695-8188
AD  - Laboratory of Cellular and Molecular Immunology, Institute of Microbiology of the 
      Czech Academy of Sciences, Prague, Czech Republic.
LA  - eng
PT  - Journal Article
DEP - 20230620
PL  - Egypt
TA  - J Immunol Res
JT  - Journal of immunology research
JID - 101627166
RN  - 0 (Transforming Growth Factor beta1)
RN  - 67763-97-7 (Insulin-Like Growth Factor II)
RN  - EC 3.4.24.35 (Matrix Metalloproteinase 9)
RN  - 0 (Tumor Necrosis Factor Inhibitors)
RN  - 0 (Vascular Endothelial Growth Factor A)
SB  - IM
MH  - Humans
MH  - *Transforming Growth Factor beta1
MH  - *Insulin-Like Growth Factor II
MH  - Matrix Metalloproteinase 9
MH  - Tumor Necrosis Factor Inhibitors
MH  - Vascular Endothelial Growth Factor A
PMC - PMC10299888
COIS- The authors declare that they have no conflicts of interest.
EDAT- 2023/06/29 13:42
MHDA- 2023/07/03 06:42
PMCR- 2023/06/20
CRDT- 2023/06/29 11:53
PHST- 2023/01/09 00:00 [received]
PHST- 2023/05/12 00:00 [revised]
PHST- 2023/05/22 00:00 [accepted]
PHST- 2023/07/03 06:42 [medline]
PHST- 2023/06/29 13:42 [pubmed]
PHST- 2023/06/29 11:53 [entrez]
PHST- 2023/06/20 00:00 [pmc-release]
AID - 10.1155/2023/1535484 [doi]
PST - epublish
SO  - J Immunol Res. 2023 Jun 20;2023:1535484. doi: 10.1155/2023/1535484. eCollection 
      2023.